公开(公告)号：EP1644019B1

公开(公告)日：2012-02-15

申请号：EP04753925.9

申请日：2004-06-01

申请人： Shire LLC

发明人： MICKLE, Travis ,  KRISHNAN, Suma ,  BISHOP, Barney ,  LAUDERBACK, Christopher ,  MONCRIEF, James, Scott ,  OBERLENDER, Rob ,  PICCARIELLO, Thomas ,  VERBICKY, Christopher A ,  PAUL, Bernhard J

IPC分类号： A61K38/00 ,  A61K47/48 ,  A61P25/00

CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y02A50/415 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

公开(公告)号：EP1644019B2

公开(公告)日：2018-02-21

申请号：EP04753925.9

申请日：2004-06-01

申请人： Shire LLC

发明人： MICKLE, Travis ,  KRISHNAN, Suma ,  BISHOP, Barney ,  LAUDERBACK, Christopher ,  MONCRIEF, James, Scott ,  OBERLENDER, Rob ,  PICCARIELLO, Thomas ,  VERBICKY, Christopher A ,  PAUL, Bernhard J

IPC分类号： A61K38/00 ,  A61K47/50 ,  A61P25/00

CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y02A50/415 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.